Vivos Therapeutics Reports Q3 Earnings Beat with Revenue of $6.41 Million
Vivos Therapeutics (VVOS) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.07, representing a beat of $0.25, while total revenue reached $6.41 million, surpassing estimates by $0.94 million despite a 5.5% year-over-year decline. In a strategic move to expand its portfolio, Vivos Therapeutics announced it will acquire a minority stake in SOD Sciences through a $12 million stock transaction. This acquisition aims to bolster the company's technological capabilities and long-term growth prospects.

Tickers: $VVOS
Topics: acquisition earnings beat revenue report stock transaction